CCR5 and Immunodeficiency: The results of dual-treatment with HAART and CCR5 inhibitors are analogous to those shown for dual-treatment with CXCR4 and CCR5 inhibitors, proving that a relatively modest additional HAART therapy (with an efficacy above 7%) obviates the risk of CCR5 inhibitors accelerating immunodeficiency in the “competitive regime” (Figure 3B).